Dysmenorrhea



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2005 Jan 15;71(2):285-291.

  Patient Information Handout

This clinical content conforms to AAFP criteria for evidence-based continuing medical education (EB CME). EB CME is clinical content presented with practice recommendations supported by evidence that has been systematically reviewed by an AAFP-approved source.

Dysmenorrhea is the leading cause of recurrent short-term school absence in adolescent girls and a common problem in women of reproductive age. Risk factors for dysmenorrhea include nulliparity, heavy menstrual flow, smoking, and depression. Empiric therapy can be initiated based on a typical history of painful menses and a negative physical examination. Nonsteroidal anti-inflammatory drugs are the initial therapy of choice in patients with presumptive primary dysmenorrhea. Oral contraceptives and depo-medroxyprogesterone acetate also may be considered. If pain relief is insufficient, prolonged-cycle oral contraceptives or intravaginal use of oral contraceptive pills can be considered. In women who do not desire hormonal contraception, there is some evidence of benefit with the use of topical heat; the Japanese herbal remedy toki-shakuyaku-san; thiamine, vitamin E, and fish oil supplements; a low-fat vegetarian diet; and acupressure. If dysmenorrhea remains uncontrolled with any of these approaches, pelvic ultrasonography should be performed and referral for laparoscopy should be considered to rule out secondary causes of dysmenorrhea. In patients with severe refractory primary dysmenorrhea, additional safe alternatives for women who want to conceive include transcutaneous electric nerve stimulation, acupuncture, nifedipine, and terbutaline. Otherwise, the use of danazol or leuprolide may be considered and, rarely, hysterectomy. The effectiveness of surgical interruption of the pelvic nerve pathways has not been established.

Primary dysmenorrhea, which is defined as painful menses in women with normal pelvic anatomy, usually begins during adolescence. It is characterized by crampy pelvic pain beginning shortly before or at the onset of menses and lasting one to three days. Dysmenorrhea also may be secondary to pelvic organ pathology.

The prevalence of dysmenorrhea is highest in adolescent women, with estimates ranging from 20 to 90 percent, depending on the measurement method used.13 About 15 percent of adolescent girls report severe dysmenorrhea,1,4 and it is the leading cause of recurrent short-term school absenteeism in adolescent girls in the United States.2,5 A longitudinal study6 of a representative cohort of Swedish women found a prevalence of dysmenorrhea of 90 percent in women 19 years of age and 67 percent in women 24 years of age. Ten percent of the 24-year-olds reported pain that interfered with daily function. Most adolescents self-medicate with over-the-counter medicines, and few consult a physician about dysmenorrhea.13

Pathogenesis

Dysmenorrhea is thought to be caused by the release of prostaglandins in the menstrual fluid, which causes uterine contractions and pain. Vasopressin also may play a role by increasing uterine contractility and causing ischemic pain as a result of vasoconstriction. Elevated vasopressin levels have been reported in women with primary dysmenorrhea.

The relationship between endometriosis and dysmenorrhea is not clear. Endometriosis may be asymptomatic, or it may be associated with pelvic pain that is not limited to the menstrual period and the low anterior pelvis. In one study7 of women undergoing elective sterilization, no difference was found in the prevalence of dysmenorrhea in women with and women without an incidental finding of endometriosis. However, an observational study8 of women undergoing laparoscopy for infertility supported a relationship between dysmenorrhea and the severity of endometriosis.

Risk Factors

Young age and nulliparity are associated with dysmenorrhea.4,9 However, one longitudinal study6 found that age was not a risk factor after controlling for parity and other factors, and that dysmenorrhea improved after childbirth. Heavy menstrual flow is associated with dysmenorrhea.4,5,9  Table 1 lists risk factors for dysmenorrhea.

TABLE 1

Risk Factors for Dysmenorrhea

Age < 20 years

Attempts to lose weight

Depression/anxiety

Disruption of social networks

Heavy menses

Nulliparity

Smoking

TABLE 1   Risk Factors for Dysmenorrhea

View Table

TABLE 1

Risk Factors for Dysmenorrhea

Age < 20 years

Attempts to lose weight

Depression/anxiety

Disruption of social networks

Heavy menses

Nulliparity

Smoking

Behavioral risk factors are of interest because of the potential to intervene. Several observational studies6,10,11 have found an association between smoking and dysmenorrhea. In women 14 to 20 years of age, attempts to lose weight are associated with increased menstrual pain independent of body mass index.12 However, the evidence of an association between overweight and dysmenorrhea is inconsistent.4,6,10 Other behaviors such as physical activity and alcohol consumption have not been associated consistently with dysmenorrhea.10,11

Mental health problems are another potentially modifiable risk factor. Depression, anxiety, and disruption of social support networks have been associated with menstrual pain.13 An association between poor self-rated overall health and dysmenorrhea has been noted,9 but socioeconomic status is not associated consistently with dysmenorrhea.5,9

Although there has been concern that tubal sterilization may be a risk factor for dysmenorrhea, a cross-sectional study14 found no difference in menstrual pain in women with and women without tubal sterilization.

Diagnosis

In most patients who present with menstrual pain, empiric therapy may be prescribed with the presumptive diagnosis of primary dysmenorrhea, based on a typical history of low anterior pelvic pain beginning in adolescence and associated specifically with menstrual periods. A history that is inconsistent and/or physical findings of a pelvic mass, abnormal vaginal discharge, or pelvic tenderness that is not limited to the time of the menstrual period suggest a diagnosis of secondary dysmenorrhea. It is appropriate to perform only an abdominal examination in young adolescents with a typical history who have never been sexually active. A pelvic examination should be performed in females who have been sexually active to screen for sexually transmitted diseases such as chlamydial infection.

When the history and physical examination suggest other pelvic pathology, the evaluation should follow accordingly, usually with pelvic ultrasonography as the initial diagnostic test to rule out anatomic abnormalities such as mass lesions. In patients with severe dysmenorrhea that is unresponsive to initial treatment, ultrasonography is useful to detect ovarian cysts and endometriomas.15 It also has reasonably good ability to detect advanced stage 3 or 4 endometriosis; its concordance with surgical staging is 84 percent.16 Sonovaginography (i.e., transvaginal ultrasonography with saline infusion of the uterus) appears to be better than transvaginal sonography alone in diagnosing rectovaginal endometriosis.17 Magnetic resonance imaging is limited in its ability to diagnose endometriosis (sensitivity, 69 percent; specificity, 75 percent).18 The reference standard test for diagnosis and staging of endometriosis is laparoscopy or laparotomy with biopsy. It should be considered when first-line therapies are ineffective and dysmenorrhea causes functional impairment.

Therapy

Table 21932  lists therapies for dysmenorrhea and the strength of evidence to support their efficacy. Many of the standard treatments have not been well studied. The recommendations reflect a balance between the available evidence and an assessment of benefit, harm, and cost. Table 3 provides dosing and cost information for prescription drugs used in the treatment of dysmenorrhea.

TABLE 2

Treatments for Dysmenorrhea

Intervention Strength of recommendation

Effective

NSAIDs19

A

Probably effective

Danazol (Danocrine)*

B

Extended-cycle oral contraceptives*

B

Hysterectomy*

B

Leuprolide acetate (Lupron)*

B

Depo-medroxyprogesterone acetate (Depo-Provera)*

B

Possibly effective

Acupuncture/acupressure20,21

B

COX-2 inhibitors22,23

B

Fish oil supplements24

B

Levonorgestrel intrauterine system (Mirena)25

B

Low-fat vegetarian diet26

B

Oral contraceptives (intravaginal administration)27

B

Oral contraceptives (oral administration)†

B

Thiamine supplementation19

B

Toki-shakuyaku-san (Japanese herb)19

B

Topical heat19

B

Transcutaneous electric nerve stimulation19

B

Vitamin E supplementation19

B

Uncertain effectiveness

Behavioral interventions including exercise19

C

Glyceryl trinitrate

C

Nifedipine (Procardia)28

C

Surgical interruption of pelvic nerve pathways29

C

Terbutaline (Bricanyl)30

C

Ineffective

Spinal manipulation31,32

B


NSAIDs = nonsteroidal anti-inflammatory drugs; COX-2 = cyclooxygenase-2.

A = consistent, good-quality, patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 225 for more information.

note: At the time of publication new information had appeared regarding the safety of COX-2 inhibitors. Because they appear to increase the risk of myocardial infarction, the decision to use these agents should only be made after a discussion of risks and benefits with the patient.

*—Mechanism: suppression of menses.

†—Based on consistent observational data.

Information from references 19 through 32.

TABLE 2   Treatments for Dysmenorrhea

View Table

TABLE 2

Treatments for Dysmenorrhea

Intervention Strength of recommendation

Effective

NSAIDs19

A

Probably effective

Danazol (Danocrine)*

B

Extended-cycle oral contraceptives*

B

Hysterectomy*

B

Leuprolide acetate (Lupron)*

B

Depo-medroxyprogesterone acetate (Depo-Provera)*

B

Possibly effective

Acupuncture/acupressure20,21

B

COX-2 inhibitors22,23

B

Fish oil supplements24

B

Levonorgestrel intrauterine system (Mirena)25

B

Low-fat vegetarian diet26

B

Oral contraceptives (intravaginal administration)27

B

Oral contraceptives (oral administration)†

B

Thiamine supplementation19

B

Toki-shakuyaku-san (Japanese herb)19

B

Topical heat19

B

Transcutaneous electric nerve stimulation19

B

Vitamin E supplementation19

B

Uncertain effectiveness

Behavioral interventions including exercise19

C

Glyceryl trinitrate

C

Nifedipine (Procardia)28

C

Surgical interruption of pelvic nerve pathways29

C

Terbutaline (Bricanyl)30

C

Ineffective

Spinal manipulation31,32

B


NSAIDs = nonsteroidal anti-inflammatory drugs; COX-2 = cyclooxygenase-2.

A = consistent, good-quality, patient-oriented evidence; B = inconsistent or limited-quality patient-oriented evidence; C = consensus, disease-oriented evidence, usual practice, opinion, or case series. See page 225 for more information.

note: At the time of publication new information had appeared regarding the safety of COX-2 inhibitors. Because they appear to increase the risk of myocardial infarction, the decision to use these agents should only be made after a discussion of risks and benefits with the patient.

*—Mechanism: suppression of menses.

†—Based on consistent observational data.

Information from references 19 through 32.

TABLE 3

Agents Used in the Treatment of Dysmenorrhea

Agent Dosage Cost (generic)*

Danazol (Danocrine)

100 or 200 mg twice daily

$172 to 286 (153 to 257)

Leuprolide acetate (Lupron)

3.75 mg IM monthly

473

NSAIDs†

Diclofenac (Voltaren)

50 mg three times daily

22 (12 to 16)

Ibuprofen (Motrin)

800 mg three times daily

6 (3 to 5)

Mefenamic acid (Ponstel)

Initial dose: 500 mg, followed by 250 mg four times daily

23

Naproxen (Naprosyn)

500 to 550 mg twice daily

13 (9 to 10)

Oral contraceptives

1 tablet daily

22 to 36


IM = intramuscularly; NSAIDs = nonsteroidal anti-inflammatory drugs; COX-2 = cyclooxygenase-2.

*—Estimated cost to the pharmacist for one month’s therapy based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2004. Cost to the patient will be higher, depending on prescription filling fee.

†—Cost for NSAIDs assumes four days of therapy per month

TABLE 3   Agents Used in the Treatment of Dysmenorrhea

View Table

TABLE 3

Agents Used in the Treatment of Dysmenorrhea

Agent Dosage Cost (generic)*

Danazol (Danocrine)

100 or 200 mg twice daily

$172 to 286 (153 to 257)

Leuprolide acetate (Lupron)

3.75 mg IM monthly

473

NSAIDs†

Diclofenac (Voltaren)

50 mg three times daily

22 (12 to 16)

Ibuprofen (Motrin)

800 mg three times daily

6 (3 to 5)

Mefenamic acid (Ponstel)

Initial dose: 500 mg, followed by 250 mg four times daily

23

Naproxen (Naprosyn)

500 to 550 mg twice daily

13 (9 to 10)

Oral contraceptives

1 tablet daily

22 to 36


IM = intramuscularly; NSAIDs = nonsteroidal anti-inflammatory drugs; COX-2 = cyclooxygenase-2.

*—Estimated cost to the pharmacist for one month’s therapy based on average wholesale prices in Red book. Montvale, N.J.: Medical Economics Data, 2004. Cost to the patient will be higher, depending on prescription filling fee.

†—Cost for NSAIDs assumes four days of therapy per month

NSAIDS

Nonsteroidal anti-inflammatory drugs (NSAIDs) are the best-established initial therapy for dysmenorrhea.19 They have a direct analgesic effect through inhibition of prostaglandin synthesis, and they decrease the volume of menstrual flow. These effects probably are common to all NSAIDs. Two meta-analyses33,34 of randomized controlled trials (RCTs) of NSAIDs and acet-aminophen found that all of the NSAIDs studied (i.e., ibuprofen [Motrin], naproxen [Naprosyn], mefenamic acid [Ponstel], and aspirin) were effective in treating women with dysmenorrhea, and all of the NSAIDs were more effective than acetaminophen.19 Small studies22,23 of cyclooxygenase-2 inhibitors have shown efficacy similar to that of NSAIDs in the treatment of dysmenorrhea. NSAIDs may be most effective when therapy is started before the onset of menstrual pain and flow, although therapy need not be continued after the end of the flow.

ORAL CONTRACEPTIVE PILLS

Treatment of dysmenorrhea is a well-accepted off-label use for oral contraceptive pills (OCPs). The proposed mechanism of action is reduced prostaglandin release during menstruation. Consistent observational data support a beneficial effect from oral contraceptives in the treatment of dysmenorrhea, and in one exploratory RCT35 of women who took desogestrel-containing OCPs, these women had less pain during menses than women who received placebo. An observational study36 of dysmenorrhea severity in women who used different forms of contraception showed lower mean scores in users of monophasic formulations compared with triphasics. However, a Cochrane review37 found insufficient evidence from RCTs to draw conclusions about the effectiveness of OCPs in treating dysmenorrhea.

OTHER HORMONAL METHODS

Several other off-label methods exist for treating dysmenorrhea with hormonal contraceptives. Most women who receive depo-medroxyprogesterone acetate (Depo-Provera) are amenorrheic within the first year of use. Similarly, extended-cycle use of OCPs (i.e., usually taking OCPs for 12 weeks followed by one week off) leads to less-frequent menstrual periods. In a retrospective review,38 21 percent of women who chose extended-cycle regimens did so primarily for treatment of dysmenorrhea. Observational data39 from users of the levonorgestrel intrauterine device (Mirena) showed a decrease in prevalence of dysmenorrhea from 60 percent before use of the device to 29 percent after 36 months of use.

A novel treatment approach is intravaginal administration of standard OCPs (i.e., 30 mcg of ethinyl estradiol and 150 mg of levonorgestrel daily); an RCT27 of 150 women found fewer systemic side effects and less dysmenorrhea with the intravaginal approach (21 percent with intravaginal use versus 44 percent with standard oral administration; number needed to treat, 4; P < .001). Contraceptive patches appear to be less effective than OCPs taken orally in treating women with dysmenorrhea.40

OTHER PHARMACOLOGIC TREATMENTS

Several medications that induce uterine relaxation have been proposed for treatment of dysmenorrhea. In one RCT,41 it was found that glyceryl trinitrate is less effective than diclofenac and is associated with a high incidence of headache. Early uncontrolled pilot studies28,30 of oral nifedipine and intravenous terbutaline showed promise, but further study on these drugs is needed.

Treatment to suppress the menstrual cycle with danazol (Danocrine) or leuprolide acetate (Lupron) may be considered, rarely, in refractory cases. These are expensive therapies with significant side effects; they usually are reserved for treatment of conditions other than primary dysmenorrhea, such as endometriosis and chronic pelvic pain that is not limited to the time of the menstrual period.

LIFESTYLE MODIFICATION

Few studies have examined the effect of lifestyle-modification interventions in the management of dysmenorrhea. One cross-over study26 of a low-fat vegetarian diet versus placebo pill showed decreased duration and intensity of dysmenorrhea in women in the intervention group. Although some studies have reported a benefit with exercise, the effect is questionable because participants were not blinded to the study hypothesis.19 Smoking cessation has not been studied as an intervention to manage dysmenorrhea.

Complementary and Alternative Medicines

SUPPLEMENTS

Thiamine at a dosage of 100 mg daily was found to be effective in treating dysmenorrhea in a double-blind RCT of more than 500 East Indian women aged 12 to 21 years with moderate to severe symptoms.19 It is unclear whether thiamine would be effective in U.S. women, whose diet may be quite different from that of Indian women. A single RCT of vitamin E found that 2,500 IU taken daily for five days starting two days before menstruation was more effective than placebo in treating dysmenorrhea.19 A small RCT24 of omega-3 polyunsaturated fatty acids found that 2 g daily of a fish oil supplement significantly reduced pain compared with placebo. High intake of fish n-3 fatty acid also was associated with less average symptom severity in an observational study of Danish women.42

HERBAL REMEDIES

The Japanese herbal remedy toki-shakuyaku-san (TSS) has been shown in an RCT to be better than placebo in the treatment of women with dysmenorrhea.19 Because this product is not regulated, the ingredients and effectiveness may vary among formulations. It does not appear to suppress fertility or ovulation. There are insufficient data to evaluate other herbal products.19

PHYSICAL TREATMENTS

Limited evidence from RCTs suggests that acupuncture and acupressure are effective in treating dysmenorrhea. In a study20 of acupuncture versus sham acupuncture, 91 percent of patients in the treatment group had pain relief compared with 36 percent of control patients. Patients in the treatment group had a 41 percent reduction in use of pain medication, while no difference was noted in control patients.20 A study21 of acupressure at a point on the hand found pain relief similar to that in patients who took ibuprofen and better than that in patients who received sham acupressure. A study43 of acupressure underwear was inconclusive because of lack of blinding.

A single small study44 of transcutaneous electric nerve stimulation (TENS) suggested that TENS is more effective in treating dysmenorrhea than a sham procedure, with 42 percent of women reporting good to excellent pain relief with TENS compared with 3 percent of control patients. However, a systematic review45 found insufficient evidence to determine if TENS is effective. In a study46 of a topical heated patch compared with low-dose ibuprofen (i.e., 400 mg three times daily) and placebo, the heated patch was as effective as ibuprofen.

A well-designed study31 of spinal manipulative therapy versus a sham procedure showed similar pain relief in both groups. In addition, a systematic review32 of spinal manipulation in the treatment of dysmenorrhea concluded that there is no evidence to suggest effectiveness.

Surgical Therapies

In rare instances, a surgical approach may be considered for women with severe, refractory dysmenorrhea. Refractory dysmenorrhea is an accepted indication for hysterectomy. Laparoscopic uterine nerve ablation (LUNA) and presacral neurectomy also have been used in refractory cases. Observational data47 show that at one year after the procedure, pain relief persisted in 82 percent of women having presacral neurectomy and in only 51 percent having LUNA. Information about long-term outcomes is relatively lacking. A Cochrane meta-analysis29 of surgical interruption of pelvic nerve pathways as a treatment for dysmenorrhea concluded that evidence was insufficient to recommend the procedure, regardless of the cause of the dysmenorrhea.

Approach to the Patient

NSAIDs are the initial therapy of choice in patients with presumptive primary dysmenorrhea. Because all NSAIDs are equal in efficacy, agent selection should be guided by cost, convenience, and patient preference, with ibuprofen or naproxen being a good choice for most patients. If hormonal contraception is desired, monophasic OCPs and depo-medroxyprogesterone acetate also may be considered. If relief is insufficient, the physician may consider prolonged-cycle OCP use or intravaginal use of OCPs.

In women who do not desire hormonal contraception, topical heat; TSS; thiamine, vitamin E, or fish oil supplements; a low-fat vegetarian diet; and acupressure are relatively simple and inexpensive alternatives that can be used alone or in combination. If dysmenorrhea is not controlled with any of these approaches, pelvic ultrasonography should be performed and referral for laparoscopy should be considered to rule out secondary causes of dysmenorrhea.48,49 In severe refractory primary dysmenorrhea, additional safe alternatives for women who want to conceive are (in order of clinical preference) TENS, acupuncture, nifedipine (Procardia), and terbutaline (Bricanyl). Otherwise, danazol or leuprolide may be considered and, rarely, hysterectomy.

Therapies on the Horizon

Several of the therapeutic approaches discussed in this article deserve further study before we can say definitively whether they are effective. Two options may become available in the near future: (1) a vasopressin-receptor antagonist is being tested. Because vasopressin appears to be involved in the pathogenesis of dysmenorrhea, vasopressin-receptor antagonists are theoretically useful. However, studies5053 to date have not shown consistent evidence of efficacy. And (2) a frameless levonorgestrel IUD has been introduced in Europe, where it is being used in the management of primary and secondary dysmenorrhea.54 The frameless device decreases menstrual flow and provides contraceptive efficacy similar to that of currently available IUDs.

The Author

LINDA FRENCH, M.D., is associate professor and associate chair for clinical services in the Department of Family Practice at Michigan State University College of Human Medicine, East Lansing. Dr. French received her medical degree from Austral University Faculty of Medicine in Valdivia, Chile, and completed a family medicine residency at Oakwood Hospital and Medical Center in Dearborn, Mich. She also completed primary care faculty development and research training fellowships at Michigan State University.

Address correspondence to Linda French, M.D., Department of Family Practice, College of Human Medicine, Michigan State University, B101 Clinical Center, East Lansing, MI 48824 (e-mail: Linda.French@hi.msu.edu). Reprints are not available from the author.

The author indicates that she does not have any conflicts of interest. Sources of funding: none reported.

REFERENCES

1. Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol. 2001;14:3–8.

2. Banikarim C, Chacko MR, Kelder SH. Prevalence and impact of dysmenorrhea on Hispanic female adolescents. Arch Pediatr Adolesc Med. 2000;154:1226–9.

3. Strinic T, Bukovic D, Pavelic L, Fajdic J, Herman I, Stipic I, et al. Anthropological and clinical characteristics in adolescent women with dysmenorrhea. Coll Antropol. 2003;27:707–11.

4. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol. 1982;144:655–60.

5. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics. 1981;68:661–4.

6. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol. 1990;97:588–94.

7. Moen MH, Stokstad T. A long-term follow-up study of women with asymptomatic endometriosis diagnosed incidentally at sterilization. Fertil Steril. 2002;78:773–6.

8. Momoeda M, Taketani Y, Terakawa N, Hoshiai H, Tanaka K, Tsutsumi O, et al. Is endometriosis really associated with pain?. Gynecol Obstet Invest. 2002;54suppl 1:18–21.

9. Teperi J, Rimpela M. Menstrual pain, health and behaviour in girls. Soc Sci Med. 1989;29:163–9.

10. Harlow SD, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women [published erratum appears in Br J Obstet Gynaecol 1997;104:386]. Br J Obstet Gynaecol. 1996;103:1134–42.

11. Parazzini F, Tozzi L, Mezzopane R, Luchini L, Marchini M, Fedele L. Cigarette smoking, alcohol consumption, and risk of primary dysmenorrhea. Epidemiology. 1994;5:469–72.

12. Montero P, Bernis C, Fernandez V, Castro S. Influence of body mass index and slimming habits on menstrual pain and cycle irregularity. J Biosoc Sci. 1996;28:315–23.

13. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol. 2001;20:411–6.

14. Harlow BL, Missmer SA, Cramer DW, Barbieri RL. Does tubal sterilization influence the subsequent risk of menorrhagia or dysmenorrhea?. Fertil Steril. 2002;77:754–60.

15. Moore J, Copley S, Morris J, Lindsell D, Golding S, Kennedy S. A systematic review of the accuracy of ultrasound in the diagnosis of endometriosis. Ultrasound Obstet Gynecol. 2002;20:630–4.

16. Exacoustos C, Zupi E, Carusotti C, Rinaldo D, Marconi D, Lanzi G, et al. Staging of pelvic endometriosis: role of sonographic appearance in determining extension of disease and modulating surgical approach. J Am Assoc Gynecol Laparosc. 2003;10:378–82.

17. Dessole S, Farina M, Rubattu G, Cosmi E, Ambrosini G, Nardelli GB. Sonovaginography is a new technique for assessing rectovaginal endometriosis. Fertil Steril. 2003;79:1023–7.

18. Stratton P, Winkel C, Premkumar A, Chow C, Wilson J, Hearns-Stokes R, et al. Diagnostic accuracy of laparoscopy, magnetic resonance imaging, and histopathologic examination for the detection of endometriosis. Fertil Steril. 2003;79:1078–85.

19. Proctor M, Farquhar C. Dysmenorrhoea. Clin Evid. 2002;(7):1639–53.

20. Helms JM. Acupuncture for the management of primary dysmenorrhea. Obstet Gynecol. 1987;69:51–6.

21. Pouresmail Z, Ibrahimzadeh R. Effects of acupressure and ibuprofen on the severity of primary dysmenorrhea. J Tradit Chin Med. 2002;22:205–10.

22. Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and pre-menstrual symptoms. Obstet Gynecol. 2000;95:245–50.

23. Daniels SE, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective in treating primary dysmenorrhea. Obstet Gynecol. 2002;100:350–8.

24. Harel Z, Biro FM, Kottenhahn RK, Rosenthal SL. Supplementation with omega-3 polyunsaturated fatty acids in the management of dysmenorrhea in adolescents. Am J Obstet Gynecol. 1996;174:1335–8.

25. Jensen JT. Noncontraceptive applications of the levo-norgestrel intrauterine system. Curr Womens Health Rep. 2002;2:417–22.

26. Malmstrom K, Kotey P, Cichanowitz N, Daniels S, Desjardins PJ. Analgesic efficacy of etoricoxib in primary dysmenorrhea: results of a randomized, controlled trial. Gynecol Obstet Invest. 2003;56:65–9.

27. Ziaei S, Rajaei L, Faghihzadeh S, Lamyian M. Comparative study and evaluation of side effects of low-dose contraceptive pills administered by the oral and vaginal route. Contraception. 2002;65:329–31.

28. Andersson KE, Ulmsten U. Effects of nifedipine on myo-metrial activity and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol. 1978;85:142–8.

29. Proctor ML, Farquhar CM, Sinclair OJ, Johnson NP. Surgical interruption of pelvic nerve pathways for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2004(3):CD001896

30. Akerlund M, Andersson KE, Ingemarsson I. Effects of terbutaline on myometrial activity, uterine blood flow, and lower abdominal pain in women with primary dysmenorrhoea. Br J Obstet Gynaecol. 1976;83:673–8.

31. Hondras MA, Long CR, Brennan PC. Spinal manipulative therapy versus a low force mimic maneuver for women with primary dysmenorrhea: a randomized, observer-blinded, clinical trial. Pain. 1999;81:105–14.

32. Proctor M, Hing W, Johnson T, Murphy P. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2004(3):CD002119

33. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol. 1998;105:780–9.

34. Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther. 2001;23:1323–38.

35. Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception. 2002;66:393–9.

36. Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception. 1990;42:497–506.

37. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev. 2001(3):CD002120

38. Sulak PJ, Kuehl TJ, Ortiz M, Shull BL. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. Am J Obstet Gynecol. 2002;186:1142–9.

39. Baldaszti E, Wimmer-Puchinger B, Loschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena): a 3-year follow-up study. Contraception. 2003;67:87–91.

40. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285:2347–54.

41. Facchinetti F, Sgarbi L, Piccinini F, Volpe A. A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea: an open, randomized, cross-over trial. Gynecol Endocrino. 2002;16:39–43.

42. Deutch B. Menstrual pain in Danish women correlated with low n-3 polyunsaturated fatty acid intake. Eur J Clin Nutr. 1995;49:508–16.

43. Taylor D, Miaskowski C, Kohn J. A randomized clinical trial of the effectiveness of an acupressure device (Relief Brief) for managing symptoms of dysmenorrhea. J Altern Complement Med. 2002;8:357–70.

44. Dawood MY, Ramos J. Transcutaneous electrical nerve stimulation (TENS) for the treatment of primary dysmenorrhea: a randomized crossover comparison with placebo TENS and ibuprofen. Obstet Gynecol. 1990;75:656–60.

45. Proctor ML, Smith CA, Farquhar CM, Stones RW. Trans-cutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev. 2002;(3):CD002123

46. Akin MD, Weingand KW, Hengehold DA, Goodale MB, Hinkle RT, Smith RP. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstet Gynecol. 2001;97:343–9.

47. Chen FP, Chang SD, Chu KK, Soong YK. Comparison of laparoscopic presacral neurectomy and laparoscopic uterine nerve ablation for primary dysmenorrhea. J Reprod Med. 1996;41:463–6.

48. Eskenazi B, Warner M, Bonsignore L, Olive D, Samuels S, Vercellini P. Validation study of nonsurgical diagnosis of endometriosis. Fertil Steril. 2001;76:929–35.

49. Frackiewicz EJ. Endometriosis: an overview of the disease and its treatment. J Am Pharm Assoc (Wash). 2000;40:645–57.

50. Akerlund M. Can primary dysmenorrhea be alleviated by a vasopressin antagonist? Results of a pilot study. Acta Obstet Gynecol Scand. 1987;66:459–61.

51. Brouard R, Bossmar T, Fournie-Lloret D, Chassard D, Akerlund M. Effect of SR49059, and orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea. BJOG. 2000;107:614–9.

52. Paranjape SB, Thibonnier M. Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opin Investig Drugs. 2001;10:825–34.

53. Valentin L, Sladkevicius P, Kindahl H, Broeders A, Marsal K, Melin P. Effects of a vasopressin antagonist on women with dysmenorrhea. Gynecol Obstet Invest. 2000;50:170–7.

54. Wildemeersch D, Schacht E, Wildemeersch P. Treatment of primary and secondary dysmenorrhea with a novel ‘frameless’ intrauterine levonorgestrel-releasing drug delivery system: a pilot study. Eur J Contracept Reprod Health Care. 2001;6:192–8.


Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article